GNS Share Price Performance
UK£23.44
3.52 (17.67%)
25.9% undervalued intrinsic discount
UK£31.63
Fair Value
Price UK£23.44
AnalystConsensusTarget UK£31.63
AnalystLowTarget UK£25.50
AnalystHighTarget UK£37.00
Fair ValueUK£31.63
Share Pricen/a
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
GNS Community Narratives
AN
Fair Value
·Fair Value UK£31.63 25.9% undervalued intrinsic discount
FDA Approval Of PRP Program In 2025 Will Open Significant Revenue Stream
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value
·Fair Value UK£25.5 8.1% undervalued intrinsic discount
Regulatory Pressures And Plant-Based Trends Will Erode Future Profitability
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value UK£37 36.6% undervalued intrinsic discount
Growing Global Protein Demand Will Accelerate Livestock Genetics
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Growing Global Protein Demand Will Accelerate Livestock Genetics
Key Takeaways Faster-than-expected regulatory progress and strategic partnerships position Genus for significant revenue and margin expansion, especially in the Chinese market. Leadership in advanced genetics and deepening presence in emerging markets strengthen Genus' premium pricing and future growth opportunities.Read more
AN
UK£37
36.6% undervalued intrinsic discount
Fair Value
Revenue
4.75% p.a.
Profit Margin
8.31%
Future PE
47.5x
Price in 2029
UK£45.77
Regulatory Pressures And Plant-Based Trends Will Erode Future Profitability
Key Takeaways Structural shifts towards alternative proteins and increased scrutiny on animal genetics threaten Genus's market relevance, revenue growth, and long-term earnings stability. Heavy R&D dependence and complex regulation expose Genus to margin compression, strained cash flows, and volatile profitability amid rising global compliance costs.Read more
AN
UK£25.5
8.1% undervalued intrinsic discount
Fair Value
Revenue
0.58% p.a.
Profit Margin
8.15%
Future PE
37.61x
Price in 2029
UK£31.48
FDA Approval Of PRP Program In 2025 Will Open Significant Revenue Stream
Key Takeaways Growth in the porcine division and strategic partnerships in China are expected to enhance Genus's revenue and earnings. Expansion in the bovine segment through acquisitions and programs like VAP is projected to improve profit margins and financial stability.Read more
AN
UK£31.63
25.9% undervalued intrinsic discount
Fair Value
Revenue
3.7% p.a.
Profit Margin
9.02%
Future PE
38.48x
Price in 2029
UK£39.04
Trending Discussion
Recently Updated Narratives
AN
GNS: Gene Editing Breakthrough And China JV Will Drive Medium Term Upside
Fair Value: UK£37 36.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
GNS: Gene Editing Progress And China JV Execution Will Shape Medium-Term Upside
Fair Value: UK£25.5 8.1% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
GNS: China JV And Gene Editing Progress Will Drive Medium Term Upside
Fair Value: UK£31.63 25.9% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Genus plc Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Sep 10, 2026
- 0.71
- 40.12%
- 7.07%
- 46.4%
About GNS
- Founded
- 1994
- Employees
- 3190
- CEO
- WebsiteView website
Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It offers dairy and beef bull semen and embryos under the Genus and Bovec brands; breeding pork and semen, as well as technical services and advice under the PIC brand. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.
Recent GNS News & Updates
GNS: Gene Editing Progress And China JV Execution Will Shape Medium-Term Upside
Analysts have raised their price target for Genus by £1.00, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change. Analyst Commentary Bearish analysts view the higher price target and updated assumptions as leaving limited room for error.
